Biphenotypic acute leukaemia: a case series

被引：42

作者：

Aribi, Ahmed

Bueso-Ramos, Carlos

Estey, Eli

Estrov, Zeev

O'Brien, Susan

Giles, Francis

Faderl, Stefan

Thomas, Deborah

Kebriaei, Partow

Garcia-Manero, Guillermo

Pierce, Sherry

Cortes, Jorge

Kantarjian, Hagop

Ravandi, Farhad

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Unit 428, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

[3] Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2007年 / 138卷 / 02期

关键词：

biphenotypic acute leukaemia; diagnosis; therapy; immnuophenotype; prognosis;

D O I：

10.1111/j.1365-2141.2007.06634.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Biphenotypic acute leukaemia (BAL) is a rare type of leukaemia. Whether patients with BAL should be treated with regimens designed for acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or both remain unclear. We have reviewed the clinical data for 31 BAL patients. Most patients co-expressed B-lymphoid and myeloid markers. No specific chromosomal abnormality was identified. The majority of the patients were treated with regimens devised for treating ALL. Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%.

引用

页码：213 / 216

页数：4

共 13 条

[1]

BAER MR, 1993, SEMIN ONCOL, V20, P6

[2]

BENE MC, 1995, LEUKEMIA, V9, P1783

[3]

BUCCHERI V, 1993, LEUKEMIA, V7, P919

[4] Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia [J].

Cortes, J ;

Estey, E ;

Beran, M ;

O'Brien, S ;

Giles, F ;

Koller, C ;

Keating, M ;

Kantarjian, H .

LEUKEMIA & LYMPHOMA, 2000, 36 (5-6) :479-484

[5]

Cortes J, 2001, CANCER-AM CANCER SOC, V92, P7, DOI 10.1002/1097-0142(20010701)92:1<7::AID-CNCR1285>3.0.CO

[6]

2-D

[7] Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside [J].

Estey, EH ;

Thall, PF ;

Giles, FJ ;

Wang, XM ;

Cortes, JE ;

Beran, M ;

Pierce, SA ;

Thomas, DA ;

Kantarjian, HM .

BLOOD, 2002, 99 (12) :4343-4349

[8]

Jaffe E.S., 2001, PATHOLOGY GENETICS T, V3

[9] Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia [J].

Kantarjian, H ;

Thomas, D ;

O'Brien, S ;

Cortes, J ;

Giles, F ;

Jeha, S ;

Bueso-Ramos, CE ;

Pierce, S ;

Shan, JQ ;

Koller, C ;

Beran, M ;

Keating, M ;

Freireich, EJ .

CANCER, 2004, 101 (12) :2788-2801

[10]

Matutes E, 1997, HAEMATOLOGICA, V82, P64

← 1 2 →